SG Americas Securities LLC Has $1.80 Million Position in Zoetis Inc. $ZTS

SG Americas Securities LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 44.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,548 shares of the company’s stock after selling 9,234 shares during the quarter. SG Americas Securities LLC’s holdings in Zoetis were worth $1,801,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Nuveen LLC bought a new position in shares of Zoetis in the 1st quarter worth $616,375,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the period. Mackenzie Financial Corp boosted its holdings in Zoetis by 4,158.3% during the first quarter. Mackenzie Financial Corp now owns 1,824,967 shares of the company’s stock worth $300,481,000 after buying an additional 1,782,110 shares during the last quarter. Polen Capital Management LLC grew its position in shares of Zoetis by 17.6% during the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the period. Finally, Impax Asset Management Group plc increased its stake in shares of Zoetis by 362.6% in the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock valued at $182,705,000 after acquiring an additional 922,589 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $115.86 on Friday. The company has a market capitalization of $51.06 billion, a price-to-earnings ratio of 19.94, a P/E/G ratio of 2.31 and a beta of 0.90. The business’s 50-day moving average price is $138.28 and its two-hundred day moving average price is $150.42. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $181.85. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period last year, the company earned $1.58 earnings per share. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday. BTIG Research reduced their price target on shares of Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. UBS Group reduced their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.